Company Overview of Iroko Pharmaceuticals Inc.
Iroko Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the development and commercialization of nonsteroidal anti-inflammatory drug therapeutics for patients to moderate acute and chronic pain. It provides Indocin for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis; and Aldomet to treat hypertension. The company’s products under development include Zorvolex, a formulation of diclofenac to treat acute pain in adult patients, as well as completed the Phase III clinical trials for the treatment of osteoarthritis pain; Tiforbex, a formulation of indomethacin that has completed the Phase III clini...
One Kew Place
150 Rouse Boulevard
Philadelphia, PA 19112
Founded in 2012
Key Executives for Iroko Pharmaceuticals Inc.
Chief Executive Officer and President
Executive Chairman of the Board
Chief Financial Officer and Principal Accounting Officer
Senior Vice President, General Counsel and Secretary
Senior Vice President and Chief Medical Officer
Compensation as of Fiscal Year 2014.
Iroko Pharmaceuticals Inc. Key Developments
Iroko Pharmaceuticals Announces International Regulatory Approval for ZORVOLEX®
Dec 10 14
Iroko Pharmaceuticals Inc. announced the Republic of Lebanon Ministry of Public Health (MOPH) has approved ZORVOLEX®, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults and osteoarthritis (OA) pain. ZORVOLEX was approved by the U.S. Food and Drug Administration (FDA) in August 2014 for the management of OA pain and in October 2013 for the treatment of mild to moderate acute pain in adults1. This regulatory approval for ZORVOLEX marks an important milestone in the international commercialization strategy for its low dose NSAID portfolio.
Iroko Pharmaceuticals Inc. Announces New Strategic Agreement to Commercialize ZORVOLEX in Australia and New Zealand
Oct 28 14
Iroko Pharmaceuticals, LLC announced that its affiliate, Iroko Pharmaceuticals Inc., signed a licensing agreement with Aspen Pharma Pty Ltd. for the exclusive rights to register and market ZORVOLEX (diclofenac) capsules in Australia and New Zealand. Aspen Pharma Pty Ltd. will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication.
Iroko Pharmaceuticals Inc. Signs New Strategic Agreement with Landsteiner Scientific, S.A. de C.V to Bring ZORVOLEX(R) to Mexico
Oct 21 14
Iroko Pharmaceuticals Inc. signed a licensing agreement with Landsteiner Scientific, S.A. de C.V., for the exclusive rights to market and sell ZORVOLEX(R) (diclofenac) capsules in Mexico. Landsteiner Scientific will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication. ZORVOLEX is approved by the United States Food and Drug Administration (FDA) for the management of mild to moderate acute pain and osteoarthritis pain. ZORVOLEX is not currently approved for marketing in any other country. Iroko will continue to retain all marketing rights to ZORVOLEX in the U.S.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries